Apogee Therapeutics, Inc (NASDAQ:APGE) Shows Bullish Momentum After Positive Trial Data But Valuation Stays Elevated
Apogee moves from clinical progress into a near-term bullish technical posture while fundamentals show heavy cash reserves alongside persistent operating losses; the immediate outlook balances momentum against a WMDST-determined over-valuation.







